Neomorph, Inc. entered into a collaboration and licensing agreement with Novo Nordisk to discover, develop and commercialize molecular glue degraders. Neomorph is a biotechnology company working to discover novel therapeutics against ‘undruggable’ targets.   Neomorph will receive an upfront and near-term milestone payments, plus R&D funding. Neomorph is also eligible to receive future clinical, commercial and sales milestones bringing the total potential deal value for multiple...